EW - Edwards Lifesciences EPS beats by $0.09 beats on revenue

Edwards Lifesciences (NYSE:EW): Q2 Non-GAAP EPS of $0.64 beats by $0.09; GAAP EPS of $0.78 beats by $0.28. Revenue of $1.38B (+49.2% Y/Y) beats by $100M. TAVR sales exceeded expectations and grew 52 percent; underlying sales grew 48 percent. Continued progress on five pivotal trials in TMTT. Q3 Guidance: The company projects sales to be between $1.29 and $1.37 billion, and adjusted EPS of $0.50 to $0.56. Raised 2021 Guidance: Sales raised to $5.2 to $5.4 billion from $4.9 to $5.3 billion; adjusted EPS raised to the high end of previous $2.07 to $2.27 range. Shares +2.13%. Press Release

For further details see:

Edwards Lifesciences EPS beats by $0.09, beats on revenue